Financial Performance - The company's operating revenue for Q1 2023 was ¥34,739,572.68, a decrease of 46.40% compared to ¥64,818,635.90 in the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥1,976,045.11, representing a decline of 1,335.77% from a profit of ¥159,904.25 in the previous year[5]. - Basic and diluted earnings per share were both -¥0.0063, a decrease of 1,360.00% from ¥0.0005 in the same period last year[5]. - Operating profit for the current period is -¥166,240.48, an improvement from -¥2,560,953.71 in the previous period[18]. - Net profit for the current period is ¥437,868.11, compared to a net loss of -¥3,237,533.29 in the previous period[18]. Cash Flow - The net cash flow from operating activities was ¥221,498.68, down 94.20% from ¥3,820,150.14 in the prior year[5]. - Cash flow from operating activities for the current period is ¥221,498.68, significantly lower than ¥3,820,150.14 in the previous period[20]. - Cash flow from investing activities shows a net outflow of -¥9,858,235.23, an improvement from -¥22,508,468.67 in the previous period[21]. - Cash flow from financing activities results in a net outflow of -¥3,440,558.04, compared to an inflow of ¥21,648,576.37 in the previous period[21]. - The ending cash and cash equivalents balance is ¥205,040,966.14, down from ¥155,964,954.55 in the previous period[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥554,426,832.54, an increase of 0.25% from ¥553,064,727.36 at the end of the previous year[5]. - The total liabilities increased slightly from 473,180,527.49 RMB to 474,104,764.56 RMB during the same period[15]. - The company's total equity as of March 31, 2023, was 80,322,067.98 RMB, up from 79,884,199.87 RMB at the beginning of the year[16]. - The cash and cash equivalents at the end of the reporting period were 205,070,966.14 RMB, compared to 218,148,260.73 RMB at the beginning of the year[13]. - The accounts receivable increased from 158,759,054.35 RMB to 168,247,960.76 RMB[13]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,088[10]. - The largest shareholder, Hunan Caixin Industrial Fund Management Co., Ltd., holds 25.58% of the shares, totaling 79,701,655 shares[10]. - The company has no preferred shareholders as of the reporting period[11]. Investment and Income - The company's investment income increased by 177.42% to ¥214,734.95 compared to a loss of ¥277,352.10 in the previous year[9]. - The company recorded a significant increase in non-operating income, totaling ¥1,000,000.00, up 761.12% from ¥116,127.27 in the previous year[9]. - The weighted average return on net assets was -15.46%, a decrease of 16.42% from 0.96% in the previous year[5]. - The company reported a 533.15% increase in trading financial assets, reaching ¥10,669,539.46, due to increased purchases of bank wealth management products[9]. Future Plans - The company plans to raise up to 276 million RMB through a private placement to supplement cash flow[12]. Audit Status - The first quarter report is not audited[22].
南华生物(000504) - 2023 Q1 - 季度财报